A Safety Study of Intravenous Infusion of Bone Marrow Mesenchymal Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia
Latest Information Update: 22 Jul 2022
At a glance
- Drugs UNEX 42 (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
Most Recent Events
- 27 May 2021 Status changed from active, no longer recruiting to discontinued due to a business decision; no safety concerns were noted.
- 24 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 28 Oct 2020 According to an United Therapeutics Corporation media release, this study was halted in Feb 2020 due to Covid 19 pandemic. However, the study has been resumed now.